Rehabilitation company Reflexion Health Monday announced encouraging results from a randomised controlled clinical trial "Virtual Exercise Rehabilitation In-home Therapy: A Research Study (VERITAS)" conducted independently by the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine.
VERITAS is the first large-scale randomised controlled clinical trial that compares virtual physical therapy with traditional physical therapy. It was designed to evaluate the cost and clinical non-inferiority of using a virtual rehabilitation platform to deliver physical therapy following total knee replacement (TKR) surgery, said the company.
In the study, VERA, the company's US FDA-cleared Virtual Exercise Rehabilitation Assistant, enabled a substantial reduction in post-acute costs and rehospitalisations, while being as effective as traditional physical therapy.
The VERITAS was a multi-centre, randomised controlled trial that enrolled 306 adult participants scheduled for TKR surgery at four US sites. The treatment group concluded with 143 adults who received the company's VERA both pre- and post-surgery, compared with a control group of 144 adults who received traditional in-home or clinic-based physical therapy at participating sites.
Clinical outcomes, health service use and costs were examined for three months after surgery. The safety endpoints for patients with virtual physical therapy were similar over traditional in-home or clinic-based physical therapy, added the company.
Additionally, the company's VERITAS study results demonstrated an average cost savings of USD2,745 per patient for those who received virtual physical therapy using VERA technology over usual care with traditional physical therapy.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML